Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. BioMarin Pharmaceutical's
Operating Income
for the
three
months ended in Mar. 2026 was €112 Mil. BioMarin Pharmaceutical's Interest Expense for the
three
months ended in Mar. 2026 was €-13 Mil.
BioMarin Pharmaceutical's interest coverage for the quarter that ended in Mar. 2026 was 8.67.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for BioMarin Pharmaceutical's Interest Coverage or its related term are showing as below:
HAM:BM8'
s Interest Coverage Range Over the Past 10 Years
Min: 4.16 Med: 24.08 Max: 37.57
Current: 13.71
HAM:BM8's Interest Coverage is ranked worse than 73.21% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs HAM:BM8: 13.71
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
BioMarin Pharmaceutical Interest Coverage Related Terms
BioMarin Pharmaceutical Interest Coverage Historical Data
* Premium members only.
The historical data trend for BioMarin Pharmaceutical's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HAM:BM8 vs CYTK, ARWR, TECH: Interest Coverage Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Interest Coverage distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (HAM:BM8) has a Interest Coverage of 8.67 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BioMarin Pharmaceutical and its competitors. This is 64% below median its historical median of 24.08. Over the past decade, BioMarin Pharmaceutical's Interest Coverage has ranged from 4.16 to 37.57. According to the industry distribution chart, BioMarin Pharmaceutical ranks #276 out of 377 companies in the Biotechnology industry, placing it in the top 73.2%.
Is BioMarin Pharmaceutical's Interest Coverage too high?
BioMarin Pharmaceutical's current Interest Coverage of 8.67 is 64% below median its 10-year median of 24.08. Over the past 10 years, this metric has ranged from a low of 4.16 to a high of 37.57. The Biotechnology industry median Interest Coverage is 106.07. BioMarin Pharmaceutical's value of 8.67 is 91.8% below this industry median. Based on the distribution chart, BioMarin Pharmaceutical ranks #276 out of 377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioMarin Pharmaceutical has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Interest Coverage compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #276 out of 377 companies for Interest Coverage. This places BioMarin Pharmaceutical in the lower half of its industry. The industry median Interest Coverage is 106.07. BioMarin Pharmaceutical's value of 8.67 is 91.8% below this benchmark. Historically, BioMarin Pharmaceutical's own Interest Coverage has ranged from 4.16 to 37.57 over the past decade. While the company's 10-year median is 24.08 vs. the industry median of 106.07, BioMarin Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMarin Pharmaceutical's current Interest Coverage of 8.67 is 91.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BioMarin Pharmaceutical and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMarin Pharmaceutical's current Interest Coverage is 8.67, which is 64% below median its own 10-year median of 24.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current Interest Coverage of 8.67. The stock's GF Value™ is €77.13, compared to a current price of €50.60 — trading 34.4% below its estimated fair value. The current Interest Coverage is 8.67, which is 64% below median its 10-year median of 24.08 and 91.8% below the Biotechnology industry median of 106.07. BioMarin Pharmaceutical's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current Interest Coverage is 8.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of €50.60 is trading 34.4% below its estimated GF Value™ of €77.13.
Key valuation signals for HAM:BM8:
Interest Coverage: 8.67 (64% below median its 10-year median of 24.08)
GF Value™: €77.13 vs. price of €50.60 (34.4% below fair value)
Industry Position: 91.8% below the Biotechnology median (#276 of 377)
No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
79GF Score
Get the complete analysis for HAM:BM8
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BM8 has been successfully added to your 
